Are We There Yet? Dynamics in the High-Dose Biologics Market and the Emergence of the Large Volume Subcutaneous Delivery Market

We will take a look at trends in the pharma pipeline for high-dose biologic subcutaneous delivery and the latest transitions from IV to SC delivery.

Identify the emerging and current use cases for high-dose biologics – let’s talk about the settings, applications and delivery approaches being deployed.

What are some of the challenges facing the market today for LVSC delivery and how might delivery approaches evolve? What are the technology options available and emerging to help serve the expanding design space. Where is the tipping point for LVSC delivery?